Hengrui PD-L1 monoanti-combination therapy has been approved for clinical use in a wide range of small cell lung cancer.

On December 24, CDE's website showed that Hengrui SHR-1316 injections were clinically implied, combined with caropherin and endocoside for initial treatment of a wide range of small cell lung cancer patients.

. SHR-1316 is a PD-L1 monoanti-drug developed by Heng Rui, which can relieve the immunosuppressive effect of PD-L1 mediated, enhance the function of lethal T cells, and play the role of mobilizing the body's immune system to remove tumor cells from the body.
next Pharma, the pharmaceutical Rubik's Cube database, the current foreign-listed SHR-1316 are Roche's Tecentriq, Pfizer/Merck's Bavencio and AstraZenic's Imfinzi.
2018, total global sales of these three products will be approximately $1,456 million. on December 9,
, AstraZeneca Imfinzi was approved by the State Drug Administration for the treatment of non-removable stage III non-small cell lung cancer, which did not progress after simultaneous chemotherapy, and the product was called Infeifan (see: The first PD-L1 monotonica was approved in China!). Stage III lung cancer treatment ushered in a heavy weapon).
.